Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression analysis after co-treatment of GSK126 and pomalidomide

ABSTRACT: Expression analysis after co-treatment of GSK126 and pomalidomide

PROVIDER: PRJNA613728 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11362316_1.fastq.gz	Fastqsanger.gz
	SRR11362316_2.fastq.gz	Fastqsanger.gz
	SRR11362317_1.fastq.gz	Fastqsanger.gz
	SRR11362317_2.fastq.gz	Fastqsanger.gz
	SRR11362318_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Expression analysis after co-treatment of GSK126 and pomalidomide

Project description:To determine combination effect of GSK126 and pomalidomide at the RNA levels in EZH2 Y641 mutant DLBCL, We performed gene expression profiling in WSU-DLCL2 cell line after co-treatment of GSK126 and pomalidomide

2020-09-23 | GSE147320 | GEO

Effects on gene expression of lapatinib and/or GSK126 treatment in SKBR3 cells

Project description:SKBR3 cells were treated with DMSO (as control), lapatinib, GSK126 or lapatinib + GSK126 for 24 h to identify genes and pathways differentially upregulated/downregulated by these treatments.

2025-12-04 | GSE304195 | GEO

Epigenetic silencing of Th1 chemokines shapes tumor immunity, immunotherapy and patient outcome [GSK126]

Project description:To define the gene profile altered by EZH2 and H3K27me3 in response to IFNg, we performed several microarrays in primary ovarian cancer cells transfected with shEZH2 or treated with GSK126. We found that 155 and 124 genes were altered by shEZH2 and GSK126 treatment, respectively, and 20 genes were increased or decreased by both shEZH2 and GSK126 treatment. Primary ovarian cancer cells were pretreated with GSK126, or transduced with a shEZH2 lentivirus, and stimulated with IFNg for 24 hours. RNA were isolated by Rneasy kit according to the manufacturer's protocol, and applied for affymetrix microarray at University of Michigan DNA Sequencing Core

2015-08-11 | E-GEOD-71869 | biostudies-arrayexpress

Epigenetic silencing of Th1 chemokines shapes tumor immunity, immunotherapy and patient outcome [GSK126]

2015-08-11 | GSE71869 | GEO

Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)

Project description:Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)

| PRJNA1231600 | ENA

Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)

Project description:Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)

| PRJNA1231602 | ENA

Effects on gene expression of lapatinib and/or GSK126 treatment in SKBR3 cells

Project description:Effects on gene expression of lapatinib and/or GSK126 treatment in SKBR3 cells

| PRJNA1299364 | ENA

Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide

Project description:This SuperSeries is composed of the following subset Series: GSE31421: Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [expression profiling] GSE31451: Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [aCGH] Refer to individual Series

2011-09-30 | E-GEOD-31452 | biostudies-arrayexpress

BMP2 and GSK126 synergize to induce expression of osteogenic genes

Project description:BMP2 and GSK126 synergize to induce expression of osteogenic genes

2019-12-01 | GSE135984 | GEO

Pomalidomide as an immune-enhancing agent in samples from people living with HIV

Project description:Persisting immune dysfunction in people living with HIV (PLHIV) on suppressive antiretroviral therapy (ART) is a key challenge to finding a cure for HIV. We investigated pomalidomide, a well-tolerated immunomodulatory drug, as an agent to enhance HIV-directed immune responses. We collected peripheral blood mononuclear cells (PBMC) from PLHIV on ART, cultured these in the presence of HIV peptides and found that pomalidomide significantly expanded tetramer-positive HIV-specific CD8+ T-cells with reduced markers of exhaustion and enhanced CD8+ T-cell-mediated killing of HIV-target cells. This was associated with an upregulation of carbon metabolism and cell cycle pathways, with MYB and BATF3 implicated as key regulators of the pomalidomide-mediated response. Pomalidomide also enhanced NK cell cytotoxicity against K562 as well as HIV-infected target cells by expanding polyfunctional cytotoxic NK cells. Given its immune-enhancing potential and good safety profile, pomalidomide should be further investigated as a therapeutic strategy for HIV control and cure.

2025-12-09 | GSE244148 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data